Pulmonary fibrosis is a potentially deadly lung disease characterized by progressive scarring and impaired lung function, with limited treatment options and a poor prognosis. Previous work found that targeting the activation, but not the production, of latent transforming growth factor 1 (TGF-β1) may offer therapeutic benefit in this condition.

Pulmonary fibrosis is a lung disease with limited therapeutic options and the development of new therapeutics is a clinical unmet need. Little is known about the role of endoplasmic reticulum stress and unfolded protein response seen in macrophages during pulmonary fibrosis.

Atyr Pharma Inc. has advanced ATYR-0101 into IND-enabling studies for pulmonary fibrosis, and is targeting an IND application in the second half of next year.

Artificial intelligence (AI) drug developer Insilico Medicine raised $110 million in a series E round led by an Asian private equity fund, Value Partners Group, that will see Insilico advance its pipeline and AI platform developments.

Artificial intelligence (AI) drug developer Insilico Medicine raised $110 million in a series E round led by an Asian private equity fund, Value Partners Group, that will see Insilico advance its pipeline and AI platform developments.

Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr expression in lung mesenchymal cells. To do that, they used a Lepr(creERT2) mouse model tracing LEPR+ alveolar fibroblasts during neonatal alveologenesis.

Pulmonary fibrosis (PF) is a chronic lung disease characterized by the replacement of normal lung tissue by scar tissue, resulting in worsening lung function and impaired gas exchange. Autotaxin (ATX), the enzyme that produces the lipid mediator lysophosphatidic acid (LPA), is upregulated in lung fibrotic tissue.